ASH 2016 Annual Meeting Highlights in Hodgkin Lymphoma
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: December 19, 2016
Expiration Date: December 19, 2017
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Health care providers, especially community-based practitioners, are challenged with attending major medical conferences, learning about new data, and understanding their relevance and potential impact on clinical practice. In this activity, participants will learn about key highlights of the most impactful and groundbreaking data in Hodgkin lymphoma (HL), presented at the 2016 American Society of Hematology (ASH) annual meeting. Leading experts in the field of HL will share their insights on a variety of abstracts, covering topics including, but not limited to: anti-CD30 therapy, immunotherapy, PET-adapted therapy, and predictive biomarkers.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in managing Hodgkin lymphoma.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with Hodgkin lymphoma (HL)
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in HL
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in HL
Immunotherapy - Stephen M. Ansell, MD, PhD
Biomarkers - Bruce D. Cheson, MD, FACP, FAAS
PET-adapted Therapy - Martin Hutchings, MD, PhD
Anti-CD30 Therapy - Alison J. Moskowitz, MD
Instructions for Participation and Credit
This activity is eligible for credit through December 19, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Stephen M. Ansell, MD, PhD
Professor of Medicine
Mayo Clinic College of Medicine
Dr. Stephen Ansell received his medical degree at the University of Pretoria, South Africa, and subsequently completed his PhD at the same institution. He trained in medical oncology before coming to the United States. He then completed a residency in internal medicine and a fellowship in hematology and oncology at Mayo Clinic. Dr. Ansell is Professor of Medicine, Mayo Clinic College of Medicine, and is a consultant in the Division of Hematology, Department of Internal Medicine, at Mayo Clinic.
Dr. Ansell is chair of both the Mayo Clinic Lymphoma Group and the Faculty Development and Recruitment for Hematology at Mayo, and has held memberships with the American Association for Cancer Research, American Medical Association, American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He has served on the editorial boards of the American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal, and Clinical Lymphoma and Myeloma. Dr. Ansell has co-authored more than 270 articles in peer-reviewed journals. His clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin disease, and Waldenström’s macroglobulinemia, and his research focuses on the biology of these diseases and on developing new therapies. Dr. Ansell has been honored with various awards during his training and career, including the Department of Medicine New Investigator at Mayo Clinic and Medical Honoree at the Lymphoma Research Foundation, Minnesota Chapter.
Bruce D. Cheson, MD, FACP, FAAS
Professor of Medicine
Head of Hematology
Deputy Chief, Hematology-Oncology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Dr. Bruce Cheson received his medical degree from Tufts University School of Medicine, Boston. He completed his internship and residency in internal medicine at the University of Virginia Hospitals, and his clinical and research fellowship in hematology at New England Medical Center Hospital. Dr. Cheson is currently Professor of Medicine, Head of Hematology, and Deputy Chief, Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center in Washington, DC. Prior to that, he was head of the Medicine Section, Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute.
Dr. Cheson has authored more than 600 medical publications and abstracts and has contributed to over 60 textbooks. He is editor-in-chief of Clinical Advances in Hematology and is on the editorial board of the Journal of Clinical Oncology. He was former editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia, and was an editor of the American College of Physicians’ Medical Knowledge Assessment Program in Oncology and the ASCO-SEP. Dr. Cheson has served on several committees of the American Society of Clinical Oncology, was on its board of directors, and edited ASCO News and ASCO Daily News. He previously served on the Oncologic Drug Advisory Committee to the U.S. Food and Drug Administration and chaired the Lymphoma Committee of the Cancer and Leukemia Group B/Alliance and the AJCC Subcommittee on Lymphoma. He is a past-chair of the scientific advisory board of the Lymphoma Research Foundation. Dr. Cheson’s clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies.
Martin Hutchings, MD, PhD
Department of Hematology
The Finsen Centre, National Hospital
Copenhagen University Hospital
Dr. Martin Hutchings received his medical degree and his PhD on PET/CT in Hodgkin lymphoma at the University of Copenhagen, Denmark. He has trained in nuclear medicine, and is pursuing specialization in clinical oncology. Dr. Hutchings is a hemato-oncologist and senior consultant in the Department of Haematology, Rigshospitalet, Copenhagen University Hospital where he is responsible for treatment of lymphoma and for Denmark’s only dedicated Phase 1 unit for experimental treatment of hematological malignancies.
Dr. Hutchings is chairman of the EORTC Lymphoma Group. He leads a number of clinical and translational studies in the field of lymphoma, with an emphasis on Hodgkin lymphoma and mantle cell lymphoma, while maintaining a special scientific interest in the role of molecular imaging of malignant lymphoma. He has written numerous journal articles and book chapters and acts as supervisor for PhD students.
Alison J. Moskowitz, MD
Memorial Sloan Kettering Cancer Center
Instructor in Medicine
Weill Cornell Medical College
New York, New York
Dr. Alison Moskowitz received her medical degree from Albert Einstein College of Medicine in the Bronx. She completed her internal medicine residency and internship at Columbia University Medical Center, followed by hematology/medical oncology fellowships at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York City. Dr. Moskowitz is an Assistant Professor and Instructor in Medicine at Weill Cornell Medical College. In addition, she is an Assistant Attending Physician, Lymphoma Service, Hematologic Oncology Division, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, New York City.
Dr. Moskowitz is board certified in internal medicine, medical oncology, and hematology. She holds professional membership in the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH), where she is also an abstract reviewer. In addition, she is an ad hoc reviewer for Blood, Lancet Oncology, British Journal of Hematology, Annals of Oncology, Haematologica, Leukemia and Lymphoma, and the Journal of Clinical Oncology, among others. Dr. Moskowitz has lectured and authored/co-authored peer-reviewed articles on autologous stem cell transplantation, relapsed/refractory Hodgkin lymphoma, and T-cell lymphoma. Her primary research focus is on evaluating novel treatments for Hodgkin lymphoma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-132-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 16-132-047
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Stephen Ansell has received grant support related to research activities from Affimed, Bristol-Myers Squibb Company, Celldex Therapeutics, Merck & Co., Inc., and Trillium Therapeutics Inc.
Dr. Bruce Cheson has received honoraria as a consultant from AbbVie Inc., Acerta Pharma, Astellas Pharma US, Inc., Celgene Corporation, Genentech - A Member of the Roche Group, Pfizer Inc., and Pharmacyclics, Inc.
Dr. Martin Hutchings has received honoraria as a consultant from Takeda Oncology. He has received grant support related to research activities from Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Dr. Alison Moskowitz has received honoraria related to speakers’ bureau activities from Takeda Oncology and honoraria as a consultant from Bristol-Myers Squibb Company.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.